Nifitinib Tosilate

托西酸伊菲替尼

Report date: 2025/03/03 14:53:51
NME

Base Information

Drug NameNifitinib Tosilate
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase Mer inhibitors
TargetsTyrosine-protein kinase Mer
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesYangzijiang Pharmaceutical Group Sichuan Hairong Pharmaceutical Co LtdSichuan University
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSichuan UniversityYangzijiang Pharmaceutical Group Sichuan Hairong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A